enVVeno Medical Corp Net Assets
enVVeno Medical Corp net assets. Based on the latest financial reports, enVVeno Medical Corp (NVNO) has net assets worth $29.45 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($32.35 Million) and total liabilities ($2.90 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore enVVeno Medical Corp equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $29.45 Million |
| % of Total Assets | 91.02% |
| Annual Growth Rate | N/A |
| 5-Year Change | 493.97% |
| 10-Year Change | N/A |
| Growth Volatility | 311.78 |
Net Assets of enVVeno Medical Corp (2014–2024)
Net assets of enVVeno Medical Corp from 2014 to 2024. This chart illustrates how enVVeno Medical Corp's net assets have evolved over time, based on quarterly financial data. See NVNO net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for enVVeno Medical Corp (2014–2024)
The table below shows the annual net assets of enVVeno Medical Corp from 2014 to 2024. For live market cap and overall valuation, see enVVeno Medical Corp market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $42.16 Million | -8.75% |
| 2023-12-31 | $46.20 Million | +19.29% |
| 2022-12-31 | $38.73 Million | -28.81% |
| 2021-12-31 | $54.40 Million | +666.49% |
| 2020-12-31 | $7.10 Million | +617.00% |
| 2019-12-31 | $989.94K | -51.39% |
| 2018-12-31 | $2.04 Million | +134.17% |
| 2017-12-31 | $-5.96 Million | -2000.55% |
| 2016-12-31 | $-283.72K | +84.06% |
| 2015-12-31 | $-1.78 Million | +11.49% |
| 2014-12-31 | $-2.01 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to enVVeno Medical Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12911815300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
enVVeno Medical Corp Net Assets Breakdown (December 2024)
enVVeno Medical Corp net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $194.01 Million | 460.20% |
| Total Equity | $42.16 Million | 100.00% |
enVVeno Medical Corp Competitors by Market Cap
The table below lists competitors of enVVeno Medical Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mangoceuticals, Inc. Common Stock
NASDAQ:MGRX
|
$4.70 Million |
|
Tribe Property Technologies Inc
V:TRBE
|
$4.70 Million |
|
Jowell Global Ltd.
NASDAQ:JWEL
|
$4.70 Million |
|
Gibb River Diamonds Ltd
AU:GIB
|
$4.71 Million |
|
THREED CAPITAL INC.
F:B5K3
|
$4.70 Million |
|
Genesis Resources Ltd
AU:GES
|
$4.70 Million |
|
Ravi Kumar Distilleries Limited
NSE:RKDL
|
$4.70 Million |
|
Erika Carmel Ltd
TA:BCUR
|
$4.69 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in enVVeno Medical Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 46,200,000 to 42,159,000, a change of -4,041,000 (-8.7%).
- Net loss of 21,819,000 reduced equity.
- New share issuances of 13,591,000 increased equity.
- Other factors increased equity by 4,187,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-21.82 Million | -51.75% |
| Share Issuances | $13.59 Million | +32.24% |
| Other Changes | $4.19 Million | +9.93% |
| Total Change | $- | -8.75% |
Book Value vs Market Value Analysis
This analysis compares enVVeno Medical Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $-10262.47 | $7.18 | x |
| 2015-12-31 | $-4973.24 | $7.18 | x |
| 2016-12-31 | $-11785.92 | $7.18 | x |
| 2017-12-31 | $-35222.95 | $7.18 | x |
| 2018-12-31 | $6655.04 | $7.18 | x |
| 2019-12-31 | $1922.21 | $7.18 | x |
| 2020-12-31 | $6734.21 | $7.18 | x |
| 2021-12-31 | $7677.70 | $7.18 | x |
| 2022-12-31 | $4224.83 | $7.18 | x |
| 2023-12-31 | $4600.68 | $7.18 | x |
| 2024-12-31 | $3012.86 | $7.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently enVVeno Medical Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -51.75%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-51.75%) is above the historical average (-157.84%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | -591.12% | 0.15x | 0.00x | $-1.20 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.43 Million |
| 2016 | 0.00% | -749.01% | 0.44x | 0.00x | $-5.46 Million |
| 2017 | 0.00% | -1845.83% | 0.19x | 0.00x | $-6.68 Million |
| 2018 | -640.47% | -6991.46% | 0.05x | 1.75x | $-13.25 Million |
| 2019 | -770.29% | -24406.74% | 0.01x | 3.47x | $-7.72 Million |
| 2020 | -128.71% | 0.00% | 0.00x | 1.48x | $-9.85 Million |
| 2021 | -30.38% | 0.00% | 0.00x | 1.06x | $-21.97 Million |
| 2022 | -63.70% | 0.00% | 0.00x | 1.08x | $-28.54 Million |
| 2023 | -50.90% | 0.00% | 0.00x | 1.05x | $-28.14 Million |
| 2024 | -51.75% | 0.00% | 0.00x | 1.07x | $-26.03 Million |
Industry Comparison
This section compares enVVeno Medical Corp's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $296,528,539
- Average return on equity (ROE) among peers: -35.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| enVVeno Medical Corp (NVNO) | $29.45 Million | 0.00% | 0.10x | $4.70 Million |
| Abbott Laboratories (ABT) | $2.83 Billion | 34.08% | 0.96x | $190.23 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $2.34 Million |
| Aethlon Medical Inc (AEMD) | $-3.66 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-11.59 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $850.46 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $2.43 Million |
| Allurion Technologies, Inc. (ALUR) | $-77.98 Million | 0.00% | 0.00x | $21.01K |
| Autonomix Medical, Inc. Common Stock (AMIX) | $5.89 Million | -283.55% | 0.29x | $1.61 Million |
| Artivion Inc (AORT) | $276.20 Million | -4.84% | 1.86x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $14.18 Million | 18.92% | 0.18x | $109.52 Million |
About enVVeno Medical Corp
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in … Read more